Editorial: Kills 99% of known germs

Transfusion

Volumn 50, Issue 8, 2010, Pages 1636-1639

  Prowse, Chris V ^a   Murphy, William G ^b  

^a SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

^b IRISH BLOOD TRANSFUSION SERVICE   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; DETERGENT; METHYLENE BLUE; SOLVENT;

BLOOD TRANSFUSION; EDITORIAL; ERYTHROCYTE; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; INCIDENT REPORT; INFECTION PREVENTION; INFECTION RISK; PATHOGEN REDUCTION TECHNOLOGY; PLASMA; RISK REDUCTION; SAFETY; THROMBOCYTE; TOXICITY; BLOOD COMPONENT THERAPY; BLOODBORNE BACTERIUM; ISOLATION AND PURIFICATION; NOTE;

BLOOD COMPONENT TRANSFUSION; BLOOD-BORNE PATHOGENS; HUMANS;

EID: 77955133943     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02776.x     Document Type: Editorial

References (16)

1. Klein HG, Anderson D, Bernardi MJ, Cable R, Carey W, Hoch JS, Robitaille N, Sivilotti ML, Smaill F. Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 2007 47 : 2338 47. (Pubitemid 350151213)
2. Vamvakas EC, Blajchman MA. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev 2010 24 : 77 124.
3. Reesink HW, Panzer S, McQuilten ZK, Wood EM, Marks DC, Wendel S, Trigo F, Biagini S, Olyntho S, Devine DV, Mumford I, Cazenave JP, Rasonglès P, Garraud O, Richard P, Schooneman F, Vezon G, Al Radwan R, Brand A, Hervig T, Castro E, Lozano M, Navarro L, Puig L, Prowse C et al. International Forum Pathogen inactivation of platelet concentrates. Vox Sang 2010 99 : 85 95.
4. Devine DV, Sher GD, Reesink HW, Panzer S, Hetzel PA, Wong JK, Horvath M, Leitner GC, Schennach H, Nussbaumer W, Genoe K, Cioffi JM, Givisiez FN, Rogerson M, Howe D, Delage G, Sarappa C, Charbonneau, Fu Y, Sarlija D, Vuk T, Strauss Patko M, Balija M, Jukić I, León de González G et al. International Forum Inventory Management. Vox Sang 2010 98 : e295 363.
5. Goodrich RP, Custer B, Keil S, Busch M. Defining "adequate" pathogen reduction performance for transfused blood components. Transfusion 2010 50 : 1827 37.
6. Murphy WG, Foley M, Doherty C, Tierney G, Kinsella A, Salami A, Cadden E, Coakley P. Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternative approach to product safety. Vox Sang 2008 95 : 13 9.
7. Dumont LJ, Kleinman S, Murphy JR, Lippincott R, Schuyler R, Houghton J, Metzel P. Screening of single-donor apheresis platelets for bacterial contamination: the PASSPORT study results. Transfusion 2010 50 : 589 99.
8. Prowse C. Zero tolerance. Transfusion 2007 47 : 1106 9.
9. Mufti NA, Erickson AC, North AK, Hanson D, Sawyer L, Corash LM, Lin L. Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals 2010 38 : 14 9.
10. Goodrich RP, Doane S, Reddy HL. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals 2010 38 : 20 30.
11. Osselaer JC, Cazenave JP, Lambermont M, Garraud O, Hidajat M, Barbolla L, Tardivel R, Defoin L, Waller C, Mendel I, Raidot JP, Kandel G, De Meuter R, Fabrigli P, Dehenau D, Arroyo JL, Padrón F, Gouezec H, Corral M, Jacquet M, Sundin D, Lin L, Corash L. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008 94 : 315 23.
12. Osselaer JC, Messe N, Hervig T, Bueno J, Castro E, Espinosa A, Accorsi P, Junge K, Jacquet M, Flament J, Corash L. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008 48 : 1061 71.
13. Cazenave JP, Waller C, Kientz D, Mendel I, Lin L, Jacquet M, Propst M, Liu W, Corash L, Sundin D, Defoin L, Messe N, Osselaer JC. An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Transfusion 2010 50 : 1210 9.
14. Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Skerrett DL, McCrae KR, Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Leissinger C, Granger S. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010 362 : 600 13.
15. Heddle NM, Cook RJ, Tinmouth A, Kouroukis CT, Hervig T, Klapper E, Brandwein JM, Szczepiorkowski ZM, AuBuchon JP, Barty RL, Lee KA, SToP Study Investigators of the BEST Collaborative. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009 113 : 1564 73.
16. Kerkhoffs J-L H, van Putten WLJ, Novotny VMJ, Te Boekhorst PAW, Schipperus MR, Zwaginga JJ, van Pampus LCM, de Greef GE, Luten M, Huijgens PC, Brand A, van Rhenen DJ. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010 May 9 [Epub ahead of print].